BioSpace News Archive

Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced positive data on CUTX-101, copper histidinate (CuHis), in patients with Menkes disease.

Assembly Biosciences, Inc. will host a webcast on Thursday, March 31, 2022 from 8:00 – 9:00 am PT/11:00 am – 12:00 pm ET to introduce its new research program focused on a novel, orally bioavailable small-molecule approach to inhibit entry of HBV and hepatitis delta virus (HDV).

Smith+Nephew, the global medical technology business, announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL.

RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks).

BD, a leading global medical technology company, provided additional details related to the planned spinoff of Embecta Corp..

Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) is pleased to announce the results of a study completed by RTI Health Solutions (RTI-HS), a leading US-based research consultancy specializing in health economics and outcomes research.

SEQENS, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, announced a multi-million-dollar investment in its research and development laboratory located in Devens, Mass.

Ribometrix announced today the promotion of Manjunath (Manju) Ramarao, Ph.D., to chief scientific officer.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), today announced the company has achieved its enrollment target of 40 patients in the EXP-6 cohort of the phase 1/2 registrational TRIDENT-1 study. EXP-6 is comprised of NTRK-positive TKI-pretreated advanced solid tumor patients.

Lexicon Pharmaceuticals, Inc. announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st Annual Scientific Session.